|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLU7 |
Gene summary for SLU7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLU7 | Gene ID | 10569 |
| Gene name | SLU7 homolog, splicing factor | |
| Gene Alias | 9G8 | |
| Cytomap | 5q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0000245 | UniProtAcc | O95391 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10569 | SLU7 | LZE2T | Human | Esophagus | ESCC | 4.74e-02 | 4.01e-01 | 0.082 |
| 10569 | SLU7 | LZE4T | Human | Esophagus | ESCC | 4.54e-22 | 3.55e-01 | 0.0811 |
| 10569 | SLU7 | LZE7T | Human | Esophagus | ESCC | 2.82e-05 | 2.08e-01 | 0.0667 |
| 10569 | SLU7 | LZE8T | Human | Esophagus | ESCC | 6.57e-08 | 1.10e-01 | 0.067 |
| 10569 | SLU7 | LZE20T | Human | Esophagus | ESCC | 1.32e-02 | 5.40e-02 | 0.0662 |
| 10569 | SLU7 | LZE24T | Human | Esophagus | ESCC | 1.45e-21 | 4.67e-01 | 0.0596 |
| 10569 | SLU7 | LZE21T | Human | Esophagus | ESCC | 1.51e-04 | 2.22e-01 | 0.0655 |
| 10569 | SLU7 | LZE6T | Human | Esophagus | ESCC | 1.13e-02 | -2.91e-03 | 0.0845 |
| 10569 | SLU7 | P1T-E | Human | Esophagus | ESCC | 1.59e-04 | 4.63e-01 | 0.0875 |
| 10569 | SLU7 | P2T-E | Human | Esophagus | ESCC | 3.67e-35 | 5.85e-01 | 0.1177 |
| 10569 | SLU7 | P4T-E | Human | Esophagus | ESCC | 4.81e-19 | 3.68e-01 | 0.1323 |
| 10569 | SLU7 | P5T-E | Human | Esophagus | ESCC | 4.11e-21 | 3.62e-01 | 0.1327 |
| 10569 | SLU7 | P8T-E | Human | Esophagus | ESCC | 2.46e-23 | 3.43e-01 | 0.0889 |
| 10569 | SLU7 | P9T-E | Human | Esophagus | ESCC | 6.42e-20 | 2.23e-01 | 0.1131 |
| 10569 | SLU7 | P10T-E | Human | Esophagus | ESCC | 3.70e-19 | 2.60e-01 | 0.116 |
| 10569 | SLU7 | P11T-E | Human | Esophagus | ESCC | 9.61e-15 | 6.68e-01 | 0.1426 |
| 10569 | SLU7 | P12T-E | Human | Esophagus | ESCC | 2.47e-21 | 5.36e-01 | 0.1122 |
| 10569 | SLU7 | P15T-E | Human | Esophagus | ESCC | 1.04e-15 | 3.37e-01 | 0.1149 |
| 10569 | SLU7 | P16T-E | Human | Esophagus | ESCC | 2.90e-24 | 3.42e-01 | 0.1153 |
| 10569 | SLU7 | P17T-E | Human | Esophagus | ESCC | 7.93e-07 | 3.41e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:0009408110 | Esophagus | ESCC | response to heat | 77/8552 | 110/18723 | 2.01e-07 | 3.11e-06 | 77 |
| GO:0034605111 | Esophagus | ESCC | cellular response to heat | 52/8552 | 69/18723 | 4.87e-07 | 6.53e-06 | 52 |
| GO:000038019 | Esophagus | ESCC | alternative mRNA splicing, via spliceosome | 55/8552 | 77/18723 | 4.07e-06 | 4.38e-05 | 55 |
| GO:000926619 | Esophagus | ESCC | response to temperature stimulus | 106/8552 | 178/18723 | 1.30e-04 | 8.84e-04 | 106 |
| GO:000024514 | Esophagus | ESCC | spliceosomal complex assembly | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:007182612 | Liver | Cirrhotic | ribonucleoprotein complex subunit organization | 115/4634 | 227/18723 | 2.67e-17 | 3.63e-15 | 115 |
| GO:002261812 | Liver | Cirrhotic | ribonucleoprotein complex assembly | 112/4634 | 220/18723 | 4.35e-17 | 5.81e-15 | 112 |
| GO:000038011 | Liver | Cirrhotic | alternative mRNA splicing, via spliceosome | 43/4634 | 77/18723 | 5.31e-09 | 2.10e-07 | 43 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLU7 | SNV | Missense_Mutation | c.60N>T | p.Met20Ile | p.M20I | O95391 | protein_coding | tolerated(0.28) | benign(0) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLU7 | SNV | Missense_Mutation | c.55N>A | p.Glu19Lys | p.E19K | O95391 | protein_coding | tolerated_low_confidence(0.7) | benign(0.006) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| SLU7 | SNV | Missense_Mutation | c.55N>A | p.Glu19Lys | p.E19K | O95391 | protein_coding | tolerated_low_confidence(0.7) | benign(0.006) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLU7 | SNV | Missense_Mutation | c.60N>A | p.Met20Ile | p.M20I | O95391 | protein_coding | tolerated(0.28) | benign(0) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| SLU7 | SNV | Missense_Mutation | c.128N>A | p.Arg43Gln | p.R43Q | O95391 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SLU7 | SNV | Missense_Mutation | novel | c.1700N>C | p.Glu567Ala | p.E567A | O95391 | protein_coding | deleterious(0) | possibly_damaging(0.505) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SLU7 | SNV | Missense_Mutation | novel | c.542N>G | p.Ile181Ser | p.I181S | O95391 | protein_coding | deleterious(0) | possibly_damaging(0.788) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SLU7 | SNV | Missense_Mutation | rs767763391 | c.390N>T | p.Lys130Asn | p.K130N | O95391 | protein_coding | deleterious(0.04) | probably_damaging(0.94) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SLU7 | SNV | Missense_Mutation | c.749N>T | p.Pro250Leu | p.P250L | O95391 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-CM-5348-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| SLU7 | SNV | Missense_Mutation | c.217N>C | p.Tyr73His | p.Y73H | O95391 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |